Audentes Therapeutics (NASDAQ: BOLD) is one of 294 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Audentes Therapeutics to related businesses based on the strength of its profitability, risk, analyst recommendations, dividends, institutional ownership, valuation and earnings.
This is a breakdown of current ratings and price targets for Audentes Therapeutics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Audentes Therapeutics Competitors||733||3175||11810||265||2.73|
Audentes Therapeutics presently has a consensus price target of $24.40, indicating a potential downside of 6.69%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 28.61%. Given Audentes Therapeutics’ rivals higher probable upside, analysts clearly believe Audentes Therapeutics has less favorable growth aspects than its rivals.
This table compares Audentes Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Audentes Therapeutics Competitors||-5,448.60%||-447.12%||-41.64%|
Insider and Institutional Ownership
77.1% of Audentes Therapeutics shares are held by institutional investors. Comparatively, 51.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 47.3% of Audentes Therapeutics shares are held by company insiders. Comparatively, 16.3% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Audentes Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Audentes Therapeutics||N/A||-$73.43 million||-7.37|
|Audentes Therapeutics Competitors||$473.33 million||$171.77 million||-6.98|
Audentes Therapeutics’ rivals have higher revenue and earnings than Audentes Therapeutics. Audentes Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Audentes Therapeutics has a beta of -0.16, meaning that its stock price is 116% less volatile than the S&P 500. Comparatively, Audentes Therapeutics’ rivals have a beta of 6.57, meaning that their average stock price is 557% more volatile than the S&P 500.
About Audentes Therapeutics
Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.
Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.